Experimental agent may help older people with chronic leukemia

May 16, 2012, Ohio State University Medical Center

The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.

The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and MD Anderson Cancer Center, indicates that the oral agent has few and a high one-year survival rate in older patients.

Ibrutinib is the first drug designed to target Bruton's tyrosine kinase, a protein that is essential for CLL-cell survival and proliferation. CLL is the most common form of , with about 16,000 new cases occurring annually in the United States. About 4,600 Americans die each year of the disease, which is incurable.

Study co-leader Dr. John C. Byrd, director of the division of hematology and a CLL specialist at OSUCCC – James, will present the findings at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"This interim report indicates that older patients respond well to this oral, targeted therapy, which lacks many of the side effects of chemotherapy and produces a quite dramatic one-year progression-free survival," says Byrd.

"The high overall response rate and lack of side effects suggests that ibrutinib deserves further study as a first-line treatment in elderly CLL patients," he says.

Standard treatment for CLL involves use of the chemotherapeutic drug fludarabine, Byrd says. These regimens can effectively control the disease until drug resistance arises, but fludarabine has serious side effects, and sometimes causes death, in older patients. For these reasons, new treatment approaches are needed for older CLL patients.

The study involves 31 patients aged 65 or older with active CLL who require stem-cell transplantation for treatment. Of these patients, 26 were randomized to receive a drug dose of 420 milligrams (mg) and five received a drug dose of 840 mg.

Of receiving 420 mg, 8 percent had no sign of disease and 65 percent showed improvement in their disease, and an estimated 93 percent would show no change in their condition.

Explore further: Novel experimental agent is highly active in CLL patients, interim study shows

Related Stories

Novel experimental agent is highly active in CLL patients, interim study shows

December 11, 2011
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...

Novel experimental agent is highly active in CLL patients, interim study shows

June 6, 2011
An interim analysis of a phase II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated both in patients who are undergoing treatment for the first ...

Agent selectively targets malignant B cells in chronic leukemia, study shows

May 3, 2011
A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James ...

Novel export-inhibitor shows promise for treating chronic lymphocytic leukemia

December 12, 2011
An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.